Abstracts tagged "microbiome"

Abstract Number: 1794 • ACR Convergence 2025
OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation
Gabriella Dyson¹, Montana Barrett¹, Nicholas Hanebutt¹, Aleksander Szymczak², Cindy Miranda Brawner¹, Pratibha Dube³, Ausitn Lopez¹, Padmaja Mehta-d'Souza¹ and Matlock Jeffries², ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Edmond, OK
Background/Purpose: MRL/MpJ (MRL) mice are protected from developing post-traumatic osteoarthritis (OA) histologic changes. We have previously shown the gut microbiome to play a key role…
Abstract Number: 0775 • ACR Convergence 2025
Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
Anastasiia Phothisane¹, Tulsi Joishy², Carolina Ramirez-Becerra¹, Zuofei Wang², Qiong Wu³, Jennifer Seifert⁴, Marie Feser⁵, Jill Norris⁶, Kristen Demoruelle⁷, LauraKay Moss⁵, Kevin Deane⁸, V. Michael Holers⁹ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of Virginia, Charlottesville, VA, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health, Denver, CO, ⁷University of Colorado Anschutz Medical Campus, Golden, CO, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Aurora
Background/Purpose: Microbial small RNAs (sRNAs) can regulate human genes, often with anti-inflammatory effects. We previously showed that an increased plasma concentration of a tRNA-derived RNA…
Abstract Number: 1792 • ACR Convergence 2025
OA protection in African spiny (Acomys) mice is partially mediated by the gut microbiome and is transferrable to wild-type mice via microbiome transplantation
Gabriella Dyson¹, Montana Barrett¹, Nicholas Hanebutt¹, Aleksander Szymczak², Cindy Miranda Brawner¹, Pratibha Dube³, Padmaja Mehta-d'Souza¹, Ashley Siefert⁴ and Matlock Jeffries², ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Edmond, OK, ⁴University of Kentucky, Lexington, KY
Background/Purpose: Mounting evidence suggests that gut microbiome shifts may be associated with knee osteoarthritis (OA) development. We have previously shown that gut microbiome transplantation from…
Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Qiguo Cui¹, Pan Wang², Bin Zhou¹ and QIn Huang³, ¹Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic), ²southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ³Nanfang Hospital, Guangzhou, China (People's Republic)
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…
Abstract Number: 1781 • ACR Convergence 2025
Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery
Aleksander Szymczak¹, Cindy Miranda Brawner², Nicholas Hanebutt², Gabriella Dyson², Montana Barrett², Anna Rapp³, Carla Scanzello⁴ and Matlock Jeffries¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³University of Pennsylavnia, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: The destabilization of the medial meniscus (DMM) model is widely used in murine OA research due to its reproducibility and ability to recapitulate key…
Abstract Number: 0491 • ACR Convergence 2025
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Kaci French¹, Luz Alvarado², Rebecca Haberman³ and Rebecca Blank³, ¹NYU Langone, New York, NY, ²NYU Langone, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Diet, the gut microbiome, and gut microbial metabolites have been implicated in rheumatoid arthritis (RA) development and modulation. Seafood based-omega-3 fatty acids modulate inflammatory…
Abstract Number: 1759 • ACR Convergence 2025
Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Abhimanyu Amarnani¹, Cristobal F. Rivera², Susan RS Gottesman³, Zakia Azad¹, Mingyang Yi⁴, Joshua Prasad⁴, Cynthia Loomis⁴, Andy Lee⁴, Nimat Ullah⁴, Bhama Ramkhelawon⁵ and Gregg J. Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University Grossman Department of Surgery, New York, ³SUNY Downstate Health Sciences University, New York, ⁴New York University Grossman School of Medicine, New York, ⁵New York University Department of Surgery, New York
Background/Purpose: SLE is an autoimmune disease that causes progressive multi-organ damage, leading to renal injury, or lupus nephritis (LN), in half of patients. Despite treatment,…
Abstract Number: 0482 • ACR Convergence 2025
R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients
Christian Furlan Freguia¹, Janet Stephens¹, Sathya Janardhanan¹, Chuck Bourne¹, Kaitlyn Skeie¹, Hudson Lowe¹, David Pascual² and Gary Fanger¹, ¹Rise Therapeutics, Rockville, MD, ²University of Wyoming, Laramie, WY
Background/Purpose: R-2487 is a novel, orally delivered, synthetic biology-based immunotherapy that utilizes Lactococcus lactis as a carrier vehicle to deliver Colonization Factor Antigen I (CFA/I)…
Abstract Number: 1565 • ACR Convergence 2025
Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
Zsuzsanna McMahan¹, Swapna Joshi², Jennifer Labus², Arissa Young², Andrea Low³, Vanessa Smith⁴, Susanna Proudman⁵, Antonia Valenzuela⁶, Phoebe Hunter⁷, Kristofer Andréasson⁸, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁹, ¹UT Health Houston, Houston, TX, ²UCLA, Los Angeles, ³Singapore General Hospital, SingHealth; Duke-NUS, Singapore, Singapore, ⁴Ghent University Hospital, Gent, Belgium, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ⁹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: GI disease is highly prevalent in systemic sclerosis (SSc) and adversely affects quality of life and survival in SSc. The pathogenesis of GI disease…
Abstract Number: 0466 • ACR Convergence 2025
Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Tulsi Joishy¹, Anastasiia Phothisane², Phicharmon Kulapatana² and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease that is thought to originate at the mucosa. Despite the mucosa’s importance, few studies have examined…
Abstract Number: 2643 • ACR Convergence 2025
Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
Rahul Bodkhe¹, Kai Trepka¹, Diego Orellana¹, Rebecca Blank², Peter Turnbaugh³, Jose Scher⁴ and Renuka Nayak⁵, ¹University of California San Francisco, San Francisco, CA, ²NYU Langone Health, New York, NY, ³University of California, San Francisco, San Francisco, CA, ⁴New York University School of Medicine, New York, NY, ⁵University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a common systemic autoimmune disease that targets the joints, causing persistent pain and swelling. Oral methotrexate (MTX) remains first-line therapy…
Abstract Number: 1338 • ACR Convergence 2025
Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins
Rebecca Blank¹, Kevin Bu², Xinyuan Zhang³, Weixi Chen⁴, Ian Cunningham⁴, jeremy sokolove⁵, Lauren Lahey⁶, Adriana Heguy⁴, Rhina Medina⁴, Carles Ubeda⁷, Renuka Nayak⁸, Jiyuan Hu⁴, Adam Cantor⁹, Jakleen Lee⁹, Frances Williams¹⁰, Jose Clemente² and Jose Scher¹¹, ¹NYU Langone Health, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Kings College London, London, United Kingdom, ⁴NYU Grossman School of Medicine, New York, ⁵odyssey, Berwyn, PA, ⁶Stanford, Palo Alto, ⁷Fisabio, Madrid, ⁸University of California, San Francisco (UCSF), San Francisco, CA, ⁹Icahn School of Medicine, New York, ¹⁰Kings College London, London, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Although genetic factors have been identified in the pathogenesis of RA, the concordance rate in monozygotic (MZ) twins is low, suggesting that other factors…
Abstract Number: 0400 • ACR Convergence 2025
Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Daniel Horton¹, Charu Verma², Sanika Rege², Alicia Iizuka², Matthew Iozzio³, Dawn Koffman³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard², Lauren Parlett⁶, Carlos Rose⁷ and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, ⁴Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ⁵New Jersey Medical School, Newark, NJ, ⁶Carelon Research, Inc, Wilmington, DE, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, New Brunswick
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatic disease, has been tied to microbiome disruption (dysbiosis). Dysbiosis in adults with arthritis affects response…
Abstract Number: 2639 • ACR Convergence 2025
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
VINOD GUPTA¹, Adam Koller¹, Benjamin Hur¹, Marissa Bailey¹, Kara Delger², Elena myasoedova¹, Vanessa Kronzer¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, ROCHESTER, MN, ²Mayo Clinic, St Charles, MN
Background/Purpose: Oral methotrexate (MTX) is the cornerstone treatment for newly diagnosed rheumatoid arthritis (RA), yet up to 50% of patients do not respond adequately. Early…
Abstract Number: 1329 • ACR Convergence 2025
Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Carolina Ramirez-Becerra¹, Tulsi Joishy², Sheau-Chiann Chen², Marisol Ramirez-Solano², Quanhu Sheng², Peter Turnbaugh³, Carles Ubeda⁴, Renuka Nayak⁵, Rebecca Blank⁶, Jose Scher⁷ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of California, San Francisco, San Francisco, CA, ⁴Fisabio, Madrid, ⁵University of California, San Francisco (UCSF), San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Microbiome and microbial products are possible contributors and predictors to methotrexate (MTX) response variability. Bacterial small RNAs (sRNAs) are found in human plasma and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].